All In Biotech

Drug Trial Radar · NCT04655118

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis

Last checked: Nov 19, 2026Latest source record: May 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

121

Planned (sponsor's estimate)

Start

Oct 22, 2020

Primary completion

Jun 30, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.

Conditions

  • Myelofibrosis
  • Indolent Systemic Mastocytosis

Interventions

  • TL-895Drug

    TL-895 is an experimental tyrosine kinase inhibitor drug taken by mouth.

  • PlaceboDrug

    Placebo to match TL-895

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohorts 1-3: Determine the RP2D of TL-895Time frame: 9 months
  2. Cohort 5: Determine the RP2D of TL-895Time frame: Week 24

Locations

52 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Colorado - Aurora Cancer Center

    Aurora, Colorado · Completed

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • Gabrail Cancer Center

    Canton, Ohio · Completed

  • University of Cincinnati (UC) Physicians Company, LLC

    Cincinnati, Ohio · Active not recruiting

  • Ohio State University

    Columbus, Ohio · Active not recruiting

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Border Medical Oncology

    East Albury, Australia · Completed

  • Southern Oncology Specialists

    Kogarah, Australia · Completed

  • Royal Perth Hospital

    Perth, Australia · Recruiting

  • St Vincent's Hospital Sydney

    Sydney, Australia · Recruiting

  • Chu De Liège

    Liège, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Belgium · Active not recruiting

  • Instituto de Estudos e Pesquisas Sao Lucas - IEP - Sao Lucas

    São Paulo, Brazil · Completed

  • University Hospital "St Ivan Rilski"

    Sofia, Bulgaria · Completed

  • Military Medical Academy

    Sofia, Bulgaria · Active not recruiting

  • CH Le Mans

    Le Mans, France · Active not recruiting

  • CHU de Nantes - Hôtel-Dieu

    Nantes, France · Completed

  • CHU de Nice - Hopital L' Archet II

    Nice, France · Completed

  • Universitaetsklinikum Carl Gustav Carus Dresden

    Dresden, Germany · Recruiting

  • Marien Hospital Duesseldorf

    Düsseldorf, Germany · Completed

  • Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall

    Halle, Germany · Recruiting

  • Universitaetsklinikum Jena

    Jena, Germany · Recruiting

  • Praxisklinik fur Hamatologie und Onkologie

    Koblenz, Germany · Completed

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary · Completed

  • Markhot Ferenc Oktatokorhaz es Rendelointezet

    Eger, Hungary · Completed

  • Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktatókórház Megyei-Városi Tüdőgondozó Intézete

    Nyíregyháza, Hungary · Completed

  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz

    Székesfehérvár, Hungary · Completed

  • Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico

    Catania, Italy · Active not recruiting

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

    Meldola, Italy · Active not recruiting

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Milan, Italy · Active not recruiting

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Active not recruiting

  • Azienda Ospedaliero Universitaria Maggiore Della Carita'

    Novara, Italy · Active not recruiting

  • Azienda Ospedaliera di Perugia-Ospedale S. Maria della Misericordia

    Perugia, Italy · Active not recruiting

  • AUSL della Romagna-Ospedale S.Maria delle Croci

    Ravenna, Italy · Active not recruiting

  • Grande Ospedale Metropolitano Bianchi Melacrino Morelli

    Reggio Calabria, Italy · Active not recruiting

  • Azienda Ospedaliero Universitaria Policlinico Umberto I

    Roma, Italy · Active not recruiting

  • Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Klinika Hematologi

    Bydgoszcz, Poland · Active not recruiting

  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii

    Gdansk, Poland · Active not recruiting

  • Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellonskiego

    Krakow, Poland · Not yet recruiting

  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku

    Wroclaw, Poland · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.